

ASX Announcement

Date: 1 September 2026

Section 708A(5)(e) disclosure notice – Issue of Ordinary Shares

Imugene Limited (ASX: IMU) (**Imugene** or **Company**) has issued 43,368,423 fully paid ordinary shares at an issue price of \$0.095 per share pursuant to the placement announced to the ASX on 07 July 2026 and as per the Appendix 2A released today and the appendix 2A released on 26 August 2026 (**Securities**).

Details of the securities issued are as follows:

Class:	Ordinary shares
ASX Code:	IMU
Date of the issue:	25 August 2026 and 1 September 2026
Total number of securities issued:	43,368,423

The Company gives notice pursuant to section 708A(5)(e) of the *Corporations Act 2001* Cth (**Corporations Act**) that:

1. the above securities have been issued without disclosure to investors under part 6D.2 Corporations Act;
2. this notice is given under section 708A(5)(e) of the Corporations Act and in accordance with section 708A(6) of the Corporations Act;
3. at the date of this notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. sections 674 and 674A of the Corporations Act; and



4. at the date of this notice, there is no information required to be disclosed by the Company which is 'excluded information' (as defined in sections 708A(7) and 708A(8) of the Corporations Act).

End

Release authorised by the Company Secretary of Imugene Limited.

For more information please contact:

General Investor Enquiries

shareholderenquiries@imugene.com

Media Enquiries

communications@imugene.com

Connect with us on LinkedIn @Imugene Limited

Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage cell therapy company developing an allogeneic CAR T for blood cancers. Our lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and together with leading specialists and medical professionals, we believe Imugene's cellular therapy may become foundation treatments for cancer. Our goal is to ensure that Imugene is at the forefront of this rapidly growing global market.